Equity awards lift Aprea (NASDAQ: APRE) CFO Hamill’s share stake

Rhea-AI Filing Summary

Aprea Therapeutics reported that SrVP/CFO/Principal Financial and Accounting Officer John P. Hamill received new equity compensation. He was granted 40,380 stock options with an exercise price of $0.765 per share, expiring on March 12, 2036.

Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting monthly over the following 36 months, contingent on continued employment. Hamill also received 10,095 restricted stock units, vesting in three equal annual installments starting March 12, 2027. Following the RSU grant, his common stock holdings total 43,528 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hamill John P.

Role SrVP/CFO/Prin Fin & Acct Ofcr

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	40,380	$0.00	--
Grant/Award	Common Stock	10,095	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 40,380 shares (Direct); Common Stock — 43,528 shares (Direct)

Footnotes (1)

1. These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamill John P.

(Last) (First) (Middle)

3805 OLD EASTON ROAD

(Street)

DOYLESTOWN PA 18902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SrVP/CFO/Prin Fin & Acct Ofcr

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		10,095(1)	A	$0.00	43,528	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$0.765	03/12/2026		A		40,380		(2)	03/12/2036	Common Stock	40,380	$0.00	40,380	D

Explanation of Responses:

1. These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

2. Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

	/s/ John Hamill	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Aprea Therapeutics (APRE) report for John P. Hamill?

Aprea reported that CFO John P. Hamill received two equity awards: 40,380 stock options with a $0.765 exercise price and 10,095 restricted stock units. Both awards are compensation grants, not open-market purchases, and vest over several years starting March 12, 2027.

How do the new stock options granted to Aprea (APRE) CFO vest?

Hamill’s 40,380 stock options vest with 25% on March 12, 2027, and the remaining 75% vesting ratably over the next 36 months. The options have a $0.765 exercise price and expire on March 12, 2036, providing long-term incentive alignment.

What are the terms of the restricted stock units granted to Aprea (APRE) CFO?

Hamill received 10,095 restricted stock units that vest in three equal annual installments starting March 12, 2027. Each installment is contingent on his continued employment through the relevant vesting date, with potential acceleration under certain conditions described in the award terms.

How many Aprea (APRE) common shares does the CFO hold after these grants?

After the reported equity awards, Hamill holds 43,528 shares of Aprea common stock. This figure reflects his direct ownership following the grant of 10,095 restricted stock units, which will settle in shares as they vest under the stated schedule and conditions.

Do the Aprea (APRE) equity awards to the CFO involve any cash transactions?

The reported awards involve no cash purchases or sales. The 40,380 stock options were granted at a $0.765 exercise price, but no exercise occurred, and the 10,095 restricted stock units are share-based compensation that will settle in common stock as they vest over time.

What conditions affect vesting of the Aprea (APRE) CFO’s equity awards?

Both the stock options and restricted stock units require Hamill’s continued employment through each vesting date. The Form 4 notes that vesting is also subject to acceleration under certain conditions, which are typically defined in the underlying award agreements and company plans.